Rick R. Suarez
Senior Vice President, Market Access
Responsibilities
Rick is responsible for leading the US Market Access team and is a member of the US Leadership Team.
Prior Experience
In his most recent role with AstraZeneca, Rick worked as Executive Director, National and Regional Payers, responsible for AstraZeneca’s US business that flows through National PBMs, health plans, acute care GPOs, as well as, the government sector. Previously, Rick was US Head of Marketing, Mature Brands, responsible for the marketing and performance of approximately ten brands. Rick has over ten years of experience in managed care leadership, including expertise in both primary care and specialty care products.
Rick’s leadership, honed in various positions throughout the company in sales, commercial operations, managed markets and marketing, has helped ensure each product’s strategy meets the needs of patients, payers, physicians, pharmacists and integrated care systems. He joined AstraZeneca in 1999 as a Pharmaceutical Sales Specialist.
Education
- Bachelor of Science, University of North Alabama, Florence, AL
Affiliations
- Member of the Academy of Managed Care Pharmacy
- Member of the Pharmaceutical Care Management Association
- Active volunteer for the National Alliance of Mental Illness (NAMI), DE chapter
Global leadership team
Our leadership, which includes our Board of Directors and Senior Executive Team represents the interests of all our stakeholders in ensuring that we deliver for patients by putting science at the heart of everything we do.
What science can do
Stories from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.
Our company
We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Join AstraZeneca
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.